Despite major advances in the medical and surgical management of atherosclerosis and its complications, atherothrombotic diseases (including myocardial infarction, stroke, and peripheral vascular disease) still cause significant morbidity and mortality. Identification of new targets and development of novel therapies directed at new and existing targets are needed to achieve further decrements in the morbidity and mortality of atherosclerosis. This proposal is focused on testing the central hypothesis that urokinase plasminogen activator (uPA), expressed by artery wall macrophages, contributes to the progression and complications of atherosclerosis. The proposal also applies insights derived from investigations of the mechanisms of uPAaccelerated atherosclerosis to design and express a uPA molecule that would be a highly effective local antithrombotic agent but would not accelerate atherosclerosis. There are 3 specific aims: (1) To test the hypothesis that macrophage-expressed uPA accelerates atherosclerosis by receptor-dependent activation of plasminogen.
This aim will be accomplished by introducing a macrophage-targeted uPA transgene into mice that are deficient in plasminogen or the uPA receptor. (2) To test the hypotheses that macrophage-expressed uPA is atherogenic at low as well as high levels in Apoe-/- mice, and that atherosclerotic plaque rupture can be caused by elevated uPA expression in macrophages in advanced atherosclerotic lesions.
This aim will be accomplished by using bone marrow transplantation to manipulate uPA expression in mouse macrophages. (3) To test the hypothesis that increased expression of uPA in the artery wall causes vasoconstriction, intimal growth, and lumen loss due to uPA receptor (uPAR)-dependent proteolytic activity and that these pathologic effects can be avoided by expression of a uPA mutant that is anchored to the endothelial cell surface.
This aim will be accomplished using adenovirus-mediated gene transfer of wild-type and mutant uPA to the rabbit carotid artery. By understanding the mechanisms through which uPA accelerates atherosclerosis, we expect to obtain insights that will permit the design and development of targeted therapies that slow the progression of atherosclerosis, prevent plaque rupture, and inhibit intravascular thrombosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL080597-05
Application #
7582287
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Hasan, Ahmed AK
Project Start
2005-05-01
Project End
2011-03-31
Budget Start
2009-04-01
Budget End
2011-03-31
Support Year
5
Fiscal Year
2009
Total Cost
$446,075
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Naik, Veena; Leaf, Elizabeth M; Hu, Jie Hong et al. (2012) Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res 94:545-54
Farris, Stephen D; Hu, Jie Hong; Krishnan, Ranjini et al. (2011) Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 286:22665-77
Hu, Jie Hong; Du, Liang; Chu, Talyn et al. (2010) Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice. Circulation 121:1637-44
Krishnan, Ranjini; Kremen, Michal; Hu, Jie Hong et al. (2009) Level of macrophage uPA expression is an important determinant of atherosclerotic lesion growth in Apoe-/- mice. Arterioscler Thromb Vasc Biol 29:1737-44
Massey, Philip G; Tanaka, Shinji; Buckler, Joshua M et al. (2009) Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains. Thromb Haemost 102:983-92
Kremen, Michal; Krishnan, Ranjini; Emery, Isaac et al. (2008) Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci U S A 105:17109-14
Stempien-Otero, April; Plawman, Abigail; Meznarich, Jessica et al. (2006) Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 281:15345-51